Present and future treatment of advanced non-small cell lung cancer

被引：21

作者：

Crinò, L ^{[1
]}

Cappuzzo, F ^{[1
]}

机构：

[1] Bellaria Hosp, Div Med Oncol, Dept Oncol, I-40039 Bologna, Italy

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 03期

关键词：

D O I：

10.1053/sonc.2002.34266

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9 / 16

页数：8

共 50 条

[21] Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial [J].

Kelly, K ;

Crowley, J ;

Bunn, PA ;

Presant, CA ;

Grevstad, PK ;

Mainpour, CM ;

Ramsey, SD ;

Wozniak, AJ ;

Weiss, GR ;

Moore, DF ;

Israel, VK ;

Livingston, RB ;

Gandara, DR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3210-3218

[22]

KOSMIDIS PA, 2000, P AM SOC CLIN ONCOL, V19, pA1908

[23] RANDOMIZED STUDY OF VINORELBINE AND CISPLATIN VERSUS VINDESINE AND CISPLATIN VERSUS VINORELBINE ALONE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - RESULTS OF A EUROPEAN MULTICENTER TRIAL INCLUDING 612 PATIENTS [J].

LECHEVALIER, T ;

BRISGAND, D ;

DOUILLARD, JY ;

PUJOL, JL ;

ALBEROLA, V ;

MONNIER, A ;

RIVIERE, A ;

LIANES, P ;

CHOMY, P ;

CIGOLARI, S ;

GOTTFRIED, M ;

RUFFIE, P ;

PANIZO, A ;

GASPARD, MH ;

RAVAIOLI, A ;

BESENVAL, M ;

BESSEN, F ;

MARTINEZ, A ;

BERTHAUD, P ;

TURSZ, T .

JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) :360-367

[24]

LECHEVALIER T, 1997, LUNG CANCER S1, V18, P13

[25] Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™) and cisplatin:: A multicenter phase II trial [J].

Manegold, C ;

Gatzemeier, U ;

von Pawel, J ;

Pirker, R ;

Malayeri, R ;

Blatter, J ;

Krejcy, K .

ANNALS OF ONCOLOGY, 2000, 11 (04) :435-440

[26] Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer [J].

Manegold, C ;

Bergman, B ;

Chemaissani, A ;

Dornoff, W ;

Drings, P ;

KellokumpuLehtinen, P ;

Liippo, K ;

Mattson, K ;

vonPawel, J ;

Ricci, S ;

Sederholm, C ;

Stahel, RA ;

Wagenius, G ;

vonWalree, N ;

tenBokkelHuinink, W .

ANNALS OF ONCOLOGY, 1997, 8 (06) :525-529

[27] Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC) [J].

Monnet, I ;

Brienza, S ;

Hugret, F ;

Voisin, S ;

Gastiaburu, J ;

Saltiel, JC ;

Soulié, P ;

Armand, JP ;

Cvitkovic, E ;

de Cremoux, H .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) :1124-1127

[28] PHASE-II STUDY OF TAXOL IN PATIENTS WITH UNTREATED ADVANCED NON-SMALL-CELL LUNG-CANCER [J].

MURPHY, WK ;

FOSSELLA, FV ;

WINN, RJ ;

SHIN, DM ;

HYNES, HE ;

GROSS, HM ;

DAVILLA, E ;

LEIMERT, J ;

DHINGRA, H ;

RABER, MN ;

KRAKOFF, IH ;

HONG, WK .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :384-388

[29]

PEREZSOLER R, 2001, P AN M AM SOC CLIN, V20, pA1235

[30] Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study [J].

Perng, RP ;

Chen, YM ;

MingLiu, J ;

Tsai, CM ;

Lin, WC ;

Yang, KY ;

WhangPeng, J .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2097-2102

← 1 2 3 4 5 →